IL-12 protects from psoriasiform skin inflammation

Paulina Kulig¹, Stephanie Musiol², Sandra Nicole Freiberger³, Bettina Schreiner¹, Gabor Gyülveszí⁴, Giancarlo Russo⁵, Stanislav Pantelyushin¹, Kenji Kishihara⁶, Francesca Alessandrini², Thomas Kündig³, Federica Sallusto⁴, Günther F.L. Hofbauer³, Stefan Haak²,* & Burkhard Becher¹,*

Neutralization of the common p40-subunit of IL-12/23 in psoriasis patients has led to a breakthrough in the management of moderate to severe disease. Aside from neutralizing IL-23, which is thought to be responsible for the curative effect, anti-p40 therapy also interferes with IL-12 signalling and type 1 immunity. Here we dissect the individual contribution of these two cytokines to the formation of psoriatic lesions and understand the effect of therapeutic co-targeting of IL-12 and IL-23 in psoriasis. Using a preclinical model for psoriatic plaque formation we show that IL-12, in contrast to IL-23, has a regulatory function by restraining the invasion of an IL-17-committed γδT (γδT17) cell subset. We discover that IL-12 receptor signalling in keratinocytes initiates a protective transcriptional programme that limits skin inflammation, suggesting that collateral targeting of IL-12 by anti-p40 monoclonal antibodies is counterproductive in the therapy of psoriasis.
Psoriasis is a chronic relapsing-remitting inflammatory skin disease that develops in genetically predisposed individuals after an unknown initial environmental, pathogenic or internal trigger. It is characterized by thickened epidermis (acanthosis), a result of keratinocyte hyper-proliferation, dysregulated keratinocyte differentiation (for example, parakeratosis), increased vascularity and accumulation of inflammatory infiltrates of T cells, neutrophils and dendritic cells. As T helper (T<sub>H</sub>)-17, T<sub>H</sub>22 and T<sub>H</sub>11 cells are found in psoriatic lesions, current understanding of the disease pathogenicity proposes a model in which activated dendritic cells and macrophages express IL-12 and IL-23, which polarize autoreactive T<sub>C</sub> cells into their subsequent effector phenotype. As IL-12 and IL-23 are detected in psoriatic lesions, targeting both cytokines concomitantly (through neutralization of the common IL-12/23p40 subunit) may have a synergetic therapeutic effect. Indeed, two anti-IL-12/23p40 monoclonal antibodies (mAbs; ustekinumab and briakinumab) have been effective in the treatment of psoriasis vulgaris, and ustekinumab is now registered for clinical use.

However, data from mouse models as well as clinical studies demonstrates the IL-23/IL-17 axis to be the dominant pathway in the pathogenesis of the disease. Repeated intradermal injections of IL-23 in mice led to development of a psoriasisform inflammatory phenotype, and IL-23-driven effector cytokines, IL-17A, IL-17F and IL-22, have been described as important factors in psoriatic plaque formation. Repeated intradermal injections of IL-23 in mice led to development of a psoriasisform inflammatory phenotype, and IL-23-driven effector cytokines, IL-17A, IL-17F and IL-22, have been described as important factors in psoriatic plaque formation. Although T<sub>H</sub>17 cells are implicated as effector cells in psoriasis, data generated in the Aldara-induced psoriatic plaque formation model show that psoriatic lesion development can be independent of T<sub>H</sub>17 cells, but relies on the activity of a specific subset of γδT cells, which are known to secrete pro-inflammatory cytokines. In concert with type 3 innate lymphoid cells, γδT cells are the major source of IL-17A, IL-17F and IL-22 in the inflamed skin.

Innate-like lymphocytes constitutively express high levels of the IL-23 receptor, making them immediate responders to IL-23 and therefore suggesting a potential role in lesion formation. IL-17A-neutralizing antibodies ixekizumab and secukinumab, as well as an IL-17A receptor-blocking antibody, brodalumab, have successfully been tested in psoriatic acid patients. First published results showed strong clinical improvement and strengthened the notion that the IL-23/IL-17 axis is essential in the pathogenesis of psoriasis. Moreover, a clinical study on anti-IL-23p19 mAb (guselkumab) confirmed a pathogenic role for de-regulated IL-23 in psoriasis.

Whereas IL-23p19 and IL-23p40 transcripts have been shown to be increased in psoriatic lesions, IL-12p35 was not. IL-12 and IL-23 are structurally related and mainly expressed by activated dendritic cells and macrophages. Despite their similarities, both cytokines trigger vastly divergent immunological pathways. IL-12 is an important factor for the differentiation of naive T cells into interferon-γ (IFN-γ)-producing T<sub>H</sub>1 cells, whereas IL-23 plays a role in sustenance of T<sub>H</sub>17 responses. It has been shown that neutralization of IL-12 leads to the amelioration of psoriasis-like skin disorder in mice. However, the antibody used was targeting the common p40 subunit, thus neutralizing both IL-12 and IL-23 (ref. 25). The therapeutic activity of the p40-specific antibody is possibly due to the inhibition of IL-23 signalling pathway and not IL-12 (ref. 26). Nonetheless, the presence of IL-12 and IL-12-induced factors has been reported in human psoriatic lesions, which suggests their potential involvement in disease pathology. The collateral inhibition of IL-12 and its potential affect on psoriasis is currently under discussion, but the actual contribution of IL-12 to the formation of psoriasiform lesions has never been addressed. Clinical studies suggest a superior efficacy through neutralization of the IL-23/IL-17 axis over blockade of IL-12/23p40 (refs 29–31). The aim of this study is to compare the individual roles of IL-12 and IL-23 in the pathophysiology of psoriatic plaque formation in vivo. We show that IL-12 opposes the pathogenic function of IL-23 in psoriatic plaque formation by signalling to the local stroma thereby restricting the cellular niche for type 17 T-cell accumulation. Our findings correct the prevailing view that IL-12 serves a primarily pro-psoriatic function during psoriatic plaque formation.

Results
Divergent roles of IL-12 and IL-23 in psoriatic inflammation.

Equally to the human disease, psoriatic lesions induced by topical Aldara treatment of mice can be reduced by application of neutralizing anti-p40 mAbs. Psoriatic plaque formation is also greatly decreased in mice deficient in p40 (Il12b<sup>−/−</sup>) (Supplementary Fig. 1). Correspondingly, critical markers of psoriasiform inflammation in this model, such as neutrophil invasion and the accumulation of IL-17A-secreting γδT cells in the lesions were reduced (Supplementary Fig. 2). To clarify the individual contributions of IL-12 and IL-23 to plaque formation we monitored the clinical disease course in mice deficient in the subunit specific to IL-12 (p35, Il12a<sup>−/−</sup>), its receptor (Il12rb2<sup>−/−</sup>) and IL-23 (p19, Il23a<sup>−/−</sup>). Whereas IL-12 is critical for type 1 immune responses, which in turn are thought to contribute to plaque formation, Il12a<sup>−/−</sup> mice (unaltered IL-23 signalling) developed significantly more severe inflammation compared with wild-type (WT) mice (Fig. 1a). Mice lacking the IL-12-specific receptor subunit (Il12rb2<sup>−/−</sup>) likewise, developed more severe lesions (Fig. 1b and Supplementary Fig. 1), pointing towards a regulatory role of IL-12 in psoriasiform lesion formation. Of note, when we compared the skin pathology of IL-23-deficient mice, Il12b<sup>−/−</sup> (lacking IL-12 and IL-23) and Il23a<sup>−/−</sup> (only lacking IL-23), we also observed a trend towards a protective effect of IL-12 (Supplementary Fig. 1).

The aggravated psoriatic plaque formation in mice defective in IL-12 signalling encompassed accelerated disease progression as well as more severe scaling and erythema, which suggested a compromised skin barrier function (Fig. 1c). For quantification of barrier integrity we measured trans-epithelial water loss (TEWL). Confirming that in the absence of IL-12 signalling Aldara treatment resulted in a more pronounced breach of epithelial barrier (Fig. 1d). Histopathological features were also more pronounced, and we observed increased frequencies of micro-abcesses, mostly consisting of neutrophils in the stratum corneum, and increased acanthosis, when IL-12 was absent (Fig. 1c,e). Cytometric quantification validated the amplified recruitment of neutrophils into the skin of Il12a<sup>−/−</sup> mice (Supplementary Fig. 3). The data collectively suggest that collateral targeting of IL-12 signalling in psoriasis could impede the therapeutic efficacy of targeting IL-23.

The prototype function of IL-12 is to induce type 1 responses and to determine whether the regulatory effect of IL-12 in plaque formation is mediated through IFN-γ, we induced Aldara lesions in Ifng<sup>−/−</sup> mice (Supplementary Fig. 4). In contrast to Il12a<sup>−/−</sup> mice, Ifng<sup>−/−</sup> mice had a slightly less severe course of disease. This demonstrates two points: (a) the protective role of IL-12 works independent of IFN-γ; and (b) IFN-γ itself is pro-inflammatory and promotes plaque formation.

To understand the molecular processes involved in the exaggeration of the psoriatic inflammatory response in IL-12 signalling-deficient compared with WT mice, transcript analysis
Figure 1 | Psoriatic plaque formation in Aldara-treated IL-12- and IL-23-deficient mice. (a,b) WT, Il12a−/−, Il23a−/− and Il12rb2−/− mice were treated with Aldara for 6 days. Back skin lesions during peak disease (day 4) represented as per cent change in skin thickness compared with untreated skin on day 0. Cumulative representation of (a) four independent experiments, (n = 12 per WT, 13 per Il12a−/− and 7 per Il23a−/−, average mean ± s.e.m.) and (b) nine independent experiments (n = 26 per WT and 27 per Il12rb2−/−, average mean ± s.e.m.). (c) Representative photos taken on day 3 post Aldara treatment. (d) Measurement of TEWL in Aldara-treated back skin. Cumulative graph of four independent experiments (n = 9 per WT and 10 per Il12rb2−/−, average mean ± s.e.m.), (e) Back skin sections stained with haematoxylin and eosin on day 4 post treatment; scale bar, 200 μm. (f) Quantification of mouse skin histology: total counts of epidermal layers and skin abscesses. Cumulative graph of 2-3 independent experiments (n = 7–9 per WT, 4 per Il12a−/− and 7–11 per Il12rb2−/−, average mean ± s.e.m.). (g) Real-time quantitative PCR analysis of the whole skin on day 5 post treatment. Cumulative graphs of three independent experiments representing fold changes relative to the average WT expression levels of independent experiments (n = 10–18 per WT and 10–15 per Il12rb2−/−). Data shown as box plots visualizing the distribution by min and max (whiskers) the 25th–75th percentile (box) and median (band). Each data point represents an individual mouse. *P < 0.05, **P < 0.01, ***P < 0.001 (a,b) one way analysis of variance (ANOVA) with Bonferroni post test, (d) two-way ANOVA with Bonferroni post test, (f-i) unpaired two-tailed t-test). NS, not significant.
of the respective lesional skin was performed (Fig. 1g–i). Hallmark pathways of psoriasis were analysed and among the cytokines IL-17A and IL-17F were elevated in the absence of IL-12Rβ2 (Fig. 1g). As expected, the inflamed skin of Il12rb2−/− mice also showed a marked decrease of IFN-γ. We thus interrogated downstream transcripts relevant to psoriasisform inflammation induced by type 17 cytokines and found a range of antimicrobial peptides to be significantly upregulated (Fig. 1h). At the same time lipocalin 2 (Lcn2) revealed increased neutrophil activity in Il12rb2−/− lesions, also indicative of an increased type 17 bias. Amongst relevant chemokines, CXCL9, which is dominantly controlled by IFN-γ, was found to be decreased (Fig. 1i). We found CCL20 to be significantly increased in the lesion of Il12rb2−/− mice (Fig. 1i). CCL20 is the ligand of CCR6, a marker of dermato-tropic type 17 effector T cells, like γδT17 and T117 cells.

**IL-12 controls invasion of Vγ6Vδ1+ γδT17 cells into the skin.** IL-17A-producing Vγ4+ γδT cells are the main drivers of the psoriasiform inflammatory processes in the skin and an established marker for disease severity16. However, the skin of Aldara-treated Il12rb2−/− mice had a distinct decrease in the frequency of these cells (Fig. 2a and Supplementary Fig. 5). The increase in total γδT cell infiltration was attained by the appearance of another γδT cell subpopulation. Those cells neither expressed the Vγ4 (characteristic for highly mobile IL-17A-secreting, skin-invading T cells) nor the Vγ5 chain of skin-resident dendritic epidermal T cells (DETCs). Whereas Vγ4−Vγ5− γδT cells can be found in low numbers in psoriatic lesion of WT mice, they accumulated in the inflamed skin of mice deficient in IL-12Rβ2 (Fig. 2a). We identified the Vγ4−Vγ5− γδT cell population as the invariant γδT cell subset expressing Vγ6Vδ1− TCR chains (Fig. 2b,c). This finding corresponds with...
the recent report, in which Vγ6+ T cells were described as an IL-17-secreting effector subset with skin-homing capacity. The overall levels of IL-17A in Il12rb2−/− and Il12rb2−/− mice were increased with Vγ6+ γδT cells being main producers of IL-17A (Fig. 3a). To determine whether the elevated levels of IL-17A are responsible for the exacerbated psoriasiform response of Il12rb2−/− animals, we found that neutralization of IL-17A led to the reduction in skin thickness, improved epidermal integrity and reduced neutrophil invasion (Fig. 3b,c and Supplementary Fig. 6). Of note, the overall cell numbers of effectors Vγ4 and Vγ6 γδT cells were not altered (Supplementary Fig. 6).

To address if Vγ6+ T cell accumulation in the skin is directly coupled to IL-12 deficiency or rather a consequence of the exaggerated inflammation in the mutant mice (Il12rb2−/− and Il12rb2−/−), we went back to the Aldara-treated Il12b and Il123a deficient mice, which both lack IL-23 and only differ in their deficiency and sufficiency of IL-12, respectively. Interestingly, we noticed that even in mice lacking IL-23 and thus, full-blown inflammation, we observed differences in Vγ6+ T cell accumulation suggesting that IL-12 regulates the γδT17 cells in the skin (Supplementary Fig. 7). To test if Vγ6+ γδT17 cell accumulation is causative in the aggravation of the disease when IL-12 is absent, we bred Vδ1−/− mice, which selectively lack functional Vγ6Vδ1+ T cells34,35 on to Il12rb2−/− background. Lack of Vγ6Vδ1+ T cells consistently reduced the exacerbated disease phenotype in Il-12 mutants (Fig. 3d), suggesting a pivotal role of the Vγ6+ γδT17 cell subset in pathogenesis under the control of IL-12. This hyper-pathogenic potential of Vγ6+ effector cells extends its biological relevance to non-mutant WT mice, as we noted a positive correlation between skin thickening—a robust clinical parameter of psoriatic plaque formation—and the ratio of Vγ6+ effectors amongst the pool of dermal γδT cells in WT mice (Pearson’s r = 0.615, P = 0.0086; Fig. 3e).

The p35 subunit is shared between two members of the IL-12 superfamily, IL-12 (p35/p40) and IL-35 (p35/EBI3). Although IL-35 has been demonstrated to have predominantly regulatory superfamily, IL-12 (p35/p40) and IL-35 (p35/EBI3). Although IL-12 (p35/p40) and IL-35 (p35/EBI3). Although IL-12 (p35/p40) and IL-35 (p35/EBI3), respectively. Interestingly, we found that neutralization of IL-23 and only differ in their deficiency and sufficiency of IL-12, respectively. Interestingly, we noticed that even in mice lacking IL-23 and thus, full-blown inflammation, we observed differences in Vγ6+ T cell accumulation suggesting that IL-12 regulates the γδT17 cells in the skin (Supplementary Fig. 7). To test if Vγ6+ γδT17 cell accumulation is causative in the aggravation of the disease when IL-12 is absent, we bred Vδ1−/− mice, which selectively lack functional Vγ6Vδ1+ T cells34,35 on to Il12rb2−/− background. Lack of Vγ6Vδ1+ T cells consistently reduced the exacerbated disease phenotype in IL-12 mutants (Fig. 3d), suggesting a pivotal role of the Vγ6+ γδT17 cell subset in pathogenesis under the control of IL-12. This hyper-pathogenic potential of Vγ6+ effector cells extends its biological relevance to non-mutant WT mice, as we noted a positive correlation between skin thickening—a robust clinical parameter of psoriatic plaque formation—and the ratio of Vγ6+ effectors amongst the pool of dermal γδT cells in WT mice (Pearson’s r = 0.615, P = 0.0086; Fig. 3e).

The p35 subunit is shared between two members of the IL-12 superfamily, IL-12 (p35/p40) and IL-35 (p35/EBI3). Although IL-35 has been demonstrated to have predominantly regulatory functions, Ebis3−/− mice did not phenocopy the aggravated pathology of IL-12 mutants, demonstrating that IL-12 and not IL-35 exerts protective functions in psoriasis (Supplementary Fig. 8). This was confirmed by local IL-12 administration, which reduced inflammation in Il12a−/− mice (Fig. 4a) but not in Il12rb2−/− mice (Fig. 4b). Correspondingly, IL-12 administration directly to the lesion diminished the invasion by γδT17 cells (Fig. 4c). We also treated WT mice with anti-IL-12p70 heterodimer-specific neutralizing antibody, and observed increased skin thickness as well as decreased skin integrity (Fig. 4d,e). The absolute numbers of inflammatory infiltrates, including neutrophils, effector γδT cells and IL-17A-producing cells were also enhanced (Fig. 4f). The combination of these loss- and gain-of-function in vivo experiments led us to conclude that IL-12, which is produced within the inflammatory lesion, limits inflammation by restricting the numbers of pathogenic γδT17 cells.

IL-12 elicits a protective programme in keratinocytes. The IL-12R complex is expressed on certain subsets of natural killer (NK) cells, NK T cells, γδT cells and activated γβT cells37. Here we show the regulation of γδT17 cell accumulation in the skin mediated by IL-12 signalling. Accordingly, we hypothesized a direct response of γδT17 cells to IL-12. For this, we determined Il12rb2 expression directly on skin-associated γδT cells (Vγ4+, Vγ6+ and Vγ5+ subsets) sorted from psoriatic WT and Il12rb2−/− skin. As expected, we found high levels of Il12rb2 RNA in Vγ5+ DETCs. However, we failed to detect Il12rb2 transcripts in the dermal Vγ4+ and Vγ6+ cell populations (Fig. 5a). IL-12 stimulation of DETCs, similarly to Tγ1 effector cells, induces a type 1 cytokine responses dominated by IFN-γ (ref. 38), which however did not mediate a protective effect of IL-12 in psoriatic plaque formation (Supplementary Fig. 4). Furthermore, DETC have been excluded from contributing to psoriatic plaque formation by a comprehensive study of Stockinger and colleagues using aryl hydrocarbon receptor mutant mice39, based on the observation that cell intrinsic aryl hydrocarbon receptor deficiency in γδT cells leads to an almost complete absence of skin-resident DETCs while other dermal γδT cell populations are not affected40,41. As we did not find a possible direct link between IL-12 and its effect on γδT cells, we screened the skin for alternative IL-12 responders. Keratinocytes actively participate in the regulation of immune responses in the psoriatic skin42,43, and there are several reports demonstrating that keratinocytes are responsive to IL-12 (refs 44–46) and that IL-12R engagement activates both STAT-3 and STAT-4 in keratinocytes, which protects against ultraviolet-mediated skin damage44.

We thus sorted CD49dhigh keratinocytes from naive WT and Il12rb2−/− mice (Supplementary Fig. 9) and detected Il12rb2 transcripts (Fig. 5a). To determine whether the IL-12R expression by keratinocytes would explain the exacerbated disease phenotype of IL-12R-deficient mice, we generated bone marrow chimeras by transferring WT (together with neonatal thymocytes to provide γδT17 cells17) into either WT or Il12rb2−/− recipients (Supplementary Fig. 10a). Aldara treatment resulted in increased skin inflammation when IL-12R was missing from the skin stroma (Fig. 5b). The majority of effector T cells present in the Aldara-treated skin were indeed of donor origin (Supplementary Fig. 10b). Again, we observed increased inflammation and leukocyte skin invasion by neutrophils and IL-17-producing T cells in the mice, where IL-12R was lacking in keratinocytes (Supplementary Fig. 10c).

These data open the possibility that in the context of psoriasiform lesion formation, not only lymphocytes but also the epidermal keratinocytes has the capacity to directly respond to IL-12. To further elaborate on this important link and to translate our findings to the human skin, we examined clinical biopsies and found ample expression of IL-12Rβ2 protein in human epidermis (Fig. 5c). Confocal microscopy further confirmed IL-12Rβ2 co-localization with the keratinocyte marker K14 (Fig. 5d). To further ascertain the cellular identity of the IL-12Rβ2-bearing stroma, we expanded human primary keratinocytes in vitro and performed immunoblotting of the IL-12Rβ2 protein. Keratinocytes had abundant IL-12Rβ2 levels comparable to activated peripheral blood mononuclear cells (PBMCs), whereas no signal was detected in unstimulated human PBMCs or monocytes (Fig. 5e and Supplementary Fig. 11). Of note, we also found IL-12Rβ2 expression in human psoriatic skin (Supplementary Fig. 12). To gain unbiased insights into the molecular processes induced by IL-12 signalling in keratinocytes, we performed transcriptomic analysis by next-generation sequencing (NGS) of sorted keratinocytes from Aldara-treated WT and Il12rb2−/− animals, at a time point before the mice display differential disease development. We identified >1,000 significantly altered expression features between the groups, conforming to a stringent significance threshold (P < 0.001; Fig. 6a). Amongst the top 100 most significant differences between Il12rb2−/− (Aldara) and WT (Aldara), we found a broad range of factors closely associated with human psoriasis48,49 as well as mouse models of the disease, for example, involucrin (Ivl), late cornified envelope 3D (Lce3d), β14 defensin (Defb14), matrix metalloproteinase 12 (Mmp12), IL-24 (Il24), serum amyloid A (Saa3), transforming growth
Figure 3 | Vγ6+ γδT17 exacerbate psoriasiform inflammation. WT, Il12rb2−/−, Il12rb2−/− and Il12rb2−/− Vd1−/− mice were treated with Aldara for 6 days. (a) Representative plots and cumulative graphs of two independent experiments depicting flow cytometry analysis of inflamed skin; cells were gated on CD45+CD11b− leukocytes and analysed for the expression of IL-17A (n = 7 per WT, 6 per Il12rb2−/− and 8 per Il12a−/−, average mean ± s.e.m.). (b,c) Representative experiment out of three depicting psoriatic plaque formation in animals treated with neutralizing antibody against IL-17A. (b) Change in skin thickness compared with untreated skin on day 0 (n = 3 per WT, 4 per Il12rb2−/− isotype and 5 per Il12rb2−/− anti-IL-17A, average mean ± s.e.m.) and (c) measurement of TEWL in Aldara-treated back skin (n = 3 per WT, 4 per Il12rb2−/− isotype and 5 per Il12rb2−/− anti-IL-17A, average mean ± s.e.m.). (d) Back plaque formation represented as per cent change in skin thickness compared with untreated skin on day 0. Cumulative graph of five independent experiments (n = 17 per WT, 15 per Il12rb2−/− and 12 per Il12rb2−/− Vd1−/−, average mean ± s.e.m.). (e) Pearson’s correlation analysis of Vγ6+ γδT cells in inflamed back skin calculated as per cent of all dermal γδT cells and per cent change in epidermal thickening in WT mice (n = 17). Each data point represents an individual mouse. **P < 0.01, ***P < 0.001 (a) unpaired two-tailed t-test, (b–d) two-way ANOVA with Bonferroni post test).
factor β2 (Tgfβ2) and different serpin peptidase inhibitors (Serpin). Figure 6b summarizes an excerpt of factors typically associated with psoriasis overlapping with those detected here. The majority of transcriptional changes found in the comparison Il12rb2−/− (Aldara) versus WT (Aldara) were in gene families typically involved in tissue structure (Supplementary Fig. 13a), keratinocyte differentiation and basement membrane integrity (Supplementary Fig. 13b). Direct immune-related changes were smaller in number but highly significant. Besides inflammatory pathways generally active
in skin inflammation like arachidonic acid metabolism and transforming growth factor-β an over-representation of inflammatory elements of the IL-17 tissue response (granulocyte colony-stimulating factor, antimicrobial peptides, IL-19/24 and IL-6) as well as a response modulator (IL-17RD) enhancing neutrophil engagement were found enhanced in IL12rb2⁻/⁻ lesions (Supplementary Fig. 13c).

We next analysed the top 10% genes selected on high variance between the Aldara-treated groups (WT versus IL12rb2⁻/⁻) and performed cluster- followed by Metacore analysis to determine the functional alterations elicited by IL-12 signalling (Fig. 6c and Supplementary Fig. 14). The result can be classified into three categories: transcripts (a) downregulated (clusters 5 and 6); (b) enhanced uniformly between the genetic groups (cluster 3); and (c) differentially regulated between the genetic groups (clusters 1, 2 and 4). Genes related to general cell metabolism and cell cycle (cluster 3) were hardly affected by IL-12 signalling in keratinocytes. Processes related to type 17 inflammation are drastically enhanced in the absence of IL-12 receptor (enriched in cluster 4; Supplementary Fig. 14), which is in agreement with the increased disease severity observed in these animals. Also, cell trafficking as well as tissue structure and remodelling (clusters 1 and 2; Supplementary Fig. 14) are affected. Unique to cluster 2 is that changes are confined to IL12rb2⁻/⁻ keratinocytes (Fig. 6c).

This is of interest since the affected pathways/processes could be involved in opening and closing a cellular niche for γδT17 cell accumulation and consequently elevated levels IL-17A within the psoriatic lesion.

We next tested if IL-12 elicits a response in primary human keratinocytes. As described previously, IL-12 alone does not significantly change the transcriptional profile of epidermal keratinocytes⁴⁷, hence we pre-activated them to simulate the significantly change the transcriptional profile of epidermal keratinocytes. As described previously, IL-12 alone does not effectively treat psoriatic lesions. This is of interest since the affected pathways/processes could be involved in opening and closing a cellular niche for γδT17 cell accumulation and consequently elevated levels IL-17A within the psoriatic lesion.

To permit a deeper statistical analysis, we performed RNaseq on three samples of primary human keratinocytes per group (TNF versus TNF + IL-12) stimulated independently. It has been previously shown that in vitro stimulation of human keratinocytes mimics the transcriptional profile of the psoriatic epidermal stroma to some extent⁵⁰, however, the changes induced by IL-12

in this in vitro model were not comparable in strength to the ex vivo analysis of keratinocytes in the psoriatic lesion of the mouse model. Despite this limitation there was a clear counter-modulation of the psoriasiform transcriptional pattern induced by TNF (refs 49,50; Fig. 6f).

Discussion

Treatment of most chronic inflammatory diseases used to imply broad immunosuppression. For the treatment of plaque-like psoriasis this has categorically changed in the last 10 years, as we are currently experiencing a rapid evolution of cytokine-blocking drugs. The initial milestone achievement was blocking of TNF, set-up to counter a number of different auto-inflammatory disorders, psoriasis being one of them³¹. Whilst effective, drug-induced TNF depletion retains to some extent the disadvantage of former approaches of a generalized immunosuppression, as well as a quota of one-third of eventual non-responders. A critical step towards better therapeutic specificity was led by early preclinical data showing that targeting of IL-12p40 successfully prevents or curbs pathology in numerous models of chronic inflammatory disease, which resulted in the development of neutralizing mAbs for clinical application⁵².⁵³ Shortly after the discovery of IL-23 in 2003, however, it became apparent that the anti-p40 therapeutic approach inadvertently counteracted two major inflammatory pathways in parallel, IL-12 and IL-23. The predominant role of IL-23 in the pathogenesis of some chronic inflammatory disease, which was previously claimed by IL-12, was first discovered in experimental autoimmune encephalomyelitis (EAE) a disease model for multiple sclerosis⁵³⁵⁵. Nonetheless, anti-p40 mAb therapy performed with unprecedented efficacy in treatment of plaque-like psoriasis for which it became FDA approved in 2009 (ustekinumab). For the treatment of psoriasis there is an on-going effort to increase the focus on the blockade of the type 17 inflammatory response, for example, by inhibition of IL-23p19 (refs 21,56) or IL-17 (refs 18–20), which in recent clinical trials exhibiting even higher efficacy than ustekinumab.⁵⁶ As predicted from the findings in preclinical models, all clinical data available to date point towards a particularly monomorphic patho-mechanism behind psoriatic plaque formation dominated by an unrestrained IL-23/17 effector response in the skin. Consequently, it seems that blocking IL-23 or even single IL-23 downstream effector molecules should be sufficient to effectively treat psoriatic lesions.

However, at present, anti-p40, inhibiting IL-12 and IL-23 signalling, is applied as standard care (ustekinumab) for moderate to severe psoriasis vulgaris in adults. Therapeutic blocking of IL-12/23p40 is well studied, and corresponding indications have been monitored in the clinical studies of the two anti-p40 mAbs, ustekinumab and briakinumab.⁵⁷⁵⁹ Taken the long-term treatment perspective of those patients and in general the delicate
Figure 5 | IL-12 responding cells in psoriatic skin. (a) WT and Il12rb2<sup>−<sup>−</sup> mice were treated with Aldara for 6 days. Vγ4<sup>+</sup>, Vγ5<sup>+</sup> and Vγ6<sup>+</sup> γδT cells were sorted by flow cytometry from WT and Il12rb2<sup>−<sup>−</sup> Aldara-treated skin, and real-time quantitative PCR analysis for Il12rb2 expression was performed. Polr2a was used as a house-keeping gene. Cumulative graph of four independent experiments (n = 4 per WT and Il12rb2<sup>−<sup>−</sup>, average mean ± s.e.m.). Keratinocytes were sorted from naive WT and Il12rb2<sup>−<sup>−</sup> animals, and Il12rb2 expression analysis was performed. Cumulative graph of three independent experiments (n = 3 per WT and Il12rb2<sup>−<sup>−</sup>, average mean ± s.e.m.). (b) Bone marrow chimeras were treated with Aldara for 7 days. Ear skin inflammation represented as a per cent change in ear thickness compared with untreated ear on day 0. Cumulative graph of four independent experiments (n = 17 per WT into WT and 16 per WT into Il12rb2<sup>−<sup>−</sup>), average mean ± s.e.m.). (c,d) Skin sections from healthy human donors were stained with antibodies against (c) human IL-12Rβ2 or total rabbit IgG for immunohistochemistry; scale bar, 50 μm, and (d) human IL-12Rβ2 or total rabbit IgG (green), K14 (red) and 4,6-diamidino-2-phenylindole (DAPI; blue) for immunofluorescent staining; scale bar, 50 μm. (e) Immunoblot analysis of IL-12Rβ2 in human primary keratinocytes. Human monocytes, naive and activated PBMCs were used as negative and positive controls; please find Supplementary Fig. 11 showing uncropped western blot data. Each data point represents an individual (a) sort of pooled material of two mice (b) mouse. ***P<0.001 ((b) two-way ANOVA with Bonferroni post test).
The prominent role of IL-12 in tumour control has been acknowledged. Indeed, briakinumab, although very effective and overall positively evaluated, showed a conspicuously increased rate of cancer in clinical studies. So far, it was hypothesized that IL-12 plays a dual role in immune-modulation. This study highlights the line between beneficial immune-modulation and detrimental immunsuppression. One concern of particular importance, considering the continuous treatment regime in psoriasis, is the different clinical studies. So far, it was hypothesized that IL-12 plays a dual role in immune-modulation. This study highlights the line between beneficial immune-modulation and detrimental immunsuppression.
blocking of IL-12 could extend the drug’s anti-inflammatory effectiveness, as presence of $T_{H}1$ cells and IFN-$\gamma$ in psoriatic lesions has been reported\textsuperscript{27}. But data on a causal relationship of either IL-12 or IFN-$\gamma$ and psoriasis was—until now—missing. At the same time data presented from past and on-going comparative clinical studies of mAbs targeting solely the IL-23/IL-17 axis versus the subunit of IL-23 and IL-12 attested a higher efficacy to the formed approach\textsuperscript{39,30}, which is in conflict with the notion of a dominant pro-psoriatic role of IL-12 in the skin. Concordant with the correlative data from patient skin biopsies we found IFN-$\gamma$ to be produced within the Aldara-induced psoriatic lesions (data not shown) and confirmed the pro-psoriatic function of IFN-$\gamma$. Here we found IL-12, which generally drives type 1 immune responses, to not only act independent of IFN-$\gamma$, but instead to suppress inflammation in the skin. Although surprising at first sight, a protective role of IL-12 in an inflammatory condition has been observed in other tissues, for example, in organ-specific autoimmune inflammation of the central nervous system. There, likewise to the clinical findings in the psoriasis model, IL-12 restrains part of the inflammatory response\textsuperscript{53,54}. Also in EAE a dual role of IL-12 is debated, as type 1 immunity is partially considered to be instrumental in disease progression and central nervous system pathology, but on the other hand the net effect of IL-12 is clearly anti-inflammatory. The mechanistic underpinning of this in EAE, however, remains largely unclear.

It is only in the past few years that the significant contribution of $\gamma$T cells in type 17-driven diseases has been explored. Also in psoriatic lesions their contribution has been noted\textsuperscript{12,63–65}, but the precise nature of their action in human inflammatory disease, as well as the translation of functional $\gamma$T cell subset identities remains unclear. Invariant $\gamma$T cells, like any innate lymphoid cell type, are low in frequency and their analysis in humans is hampered by the typically small sizes of tissue biopsies. With the data available to date it is hard to predict whether a homologue or functional orthologue of V$\gamma$6$^+$$\gamma$T17 cells exists in humans and if accumulation of such cells is affected by IL-12. In mice, the presence of IL-12 prevents the unbridled accumulation of V$\gamma$6$^+$ type 17 cells, independent of V$\gamma$4$^+$ $\gamma$T17 cells, resulting in a net surplus of IL-17. Importantly, IL-12 did not affect skin-invading $\gamma$T17 cells directly.

Whereas TNF or IL-1$\beta$ have long been recognized to interact with both haematopoietic and stromal cells, here we describe that IL-12 too can directly communicate with the stromal microenvironment, independent of its function in immune cells. In contrast to mediators such as TNF or IL-1$\beta$, which exacerbate epithelial inflammation\textsuperscript{66}, IL-12 initiates a tissue-protective response in keratinocytes. Moreover, IL-12 counter-regulated the psoriatic transcriptional signature in both murine and human keratinocytes. IL-12 specifically modifies transcriptional programmes affecting tissue structure remodelling, which in turn could affect immune cell accumulation and recruitment allowing available pathogenic lymphocytes to populate the tissue. In the Aldara-induced psoriasis model, the cells accumulating in IL-12-deficient tissue are predominantly V$\gamma$6$^+$ type 17 cells. The increase in net IL-17 activates the local stroma (for example, keratinocytes) amplifying the type 17 signature in the tissue, which can explain the drastic increase in neutrophil influx and epidermal micro-abscesses in Il12a$^{-/-}$ mice.

Thus, while our data causally relate psoriasis to be a bona fide type 17 inflammatory disorder with minor contribution of type 1 effector response, we additionally demonstrate that IL-12 mediates an autonomous regulatory programme in the skin. Whether these preclinical findings can be fully translated to human patients remains to be established, however, it does offer a lead towards understanding the higher clinical efficacy of anti-1p19 and anti-IL-17 drugs compared with ustekinumab (anti-p40) in psoriasis vulgaris patients. The observed anti-psoriatic effect of IL-12 may not be exclusively mediated through its impact on the keratinocyte compartment, and additional IL-12-responsive cell types may contribute. Nonetheless, we conclude that collateral targeting of IL-12 with anti-p40 mAbs in the treatment of psoriasis might carry more risk than benefit and even be counterproductive, which warrants further translational investigation.

**Methods**

**Mice.** C57BL/6 were purchased from Janvier (Saint Berthevin, France). Il12a$^{-/-}$, Il12b$^{-/-}$, Ebi3$^{-/-}$, Il17a$^{-/-}$ and Il17ra$^{-/-}$ were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and Regeneron (Tarrytown, NY, USA), respectively. Il12b$^{-/-}$ mice were purchased from Jackson Laboratory or provided by E. von Stebut and K. Schonwenberg (Mainz, Germany). Vd1$^{-/-}$ animals were provided by K. Kishihara (Nagasaki, Japan). Mice were kept in house under specific pathogen-free conditions. Animal experiments were approved by the Swiss Cantonal Veterinary Office (33/2010 and 68/2013).

**Aldara treatment.** The 7- to 11-week-old female mice (cf. figure legends) of similar body weight and synchronized hair cycle were used for all experiments. Back skin of mice was shaved and depilated, and 48 h later 55 mg of Aldara cream (5% IMQ; 3M Pharmaceuticals, Maplewood, MN, USA) was applied daily for 2 or 5–6 consecutive days. When entire skin was used 7 mg of Aldara was applied on each ear for 6–7 consecutive days. Back skin or ear thickness was measured daily with a digital calliper. Skin inflammation is represented as a per cent change in the skin thickness compared with untreated skin on day 0. IL-12Fc/PBS treatment was performed by local subcutaneous injection of 200 ng of IL-12Fc (ref. 67) or PBS per ear. Mice were injected every second day starting on day −1. Anti-IL-17A (1F73, BioXcell, West Lebanon, NH, USA) or isotype control (MOPC-21, BioXcell), anti-IL-12p75 (R2-9A5, BioXcell) or isotype control (LT-2, BioXcell) antibodies were injected intraperitoneally. Mice received 200 μg of antibodies every second day starting on day −1.

**Group sizes.** Groups were at least two experimental versus two control mice, but most of the time three versus three or more. Mouse numbers and experiment numbers are stated in the individual figure legends. All individual experiments showed the phenotypes depicted by the cumulative graphs. Mice of different experimental groups were mixed in the cages and the order in which individual mice were picked for Aldara treatment or any measurements was random. All experiments were blinded for disease induction and experimental read-outs.

**TEWL measurement.** TEWL of dorsal skin was measured during the course of Aldara-induced plaque formation by use of an evaporimeter equipped with a closed chamber probe (Aquaflux AF200, Biox System Ltd, London, UK).

**Mouse skin leukocyte isolation.** Back skin or ears were cut into small pieces and digested for 1 h at 37°C in RPMI 1640 (PAN-Biotech, Aidenbach, Germany) medium containing 1 mg ml$^{-1}$ collagenase type IV (Sigma-Aldrich, St Louis, MO, USA) and 0.5 mg ml$^{-1}$ dispase (Roche). Afterwards, the epidermis was separated manually with 250 rad with 24 h interval) before receiving 5000 rad (17F3, BioXcell, West Lebanon, NH, USA) or isotype control (MOPC-21, BioXcell). Cells were filtered with a 70 μm cell strainer to receive single-cell suspension.

**Mouse keratinocyte isolation.** For real-time quantitative PCR analysis, as well as NGS back skin was incubated for 2 h at 37°C in HBSs buffer (Gibco) containing 2.4 mg ml$^{-1}$ of dispase (Roche, Switzerland), next cut into small pieces and digested for another hour at 37°C in HBSs buffer containing 10% FCS, 0.4 mg ml$^{-1}$ collagenase type IV (Sigma-Aldrich) and 0.1 mg ml$^{-1}$ DNase (Sigma-Aldrich). Cells were filtered with a 70 μm cell strainer to receive single-cell suspension.

**Bone marrow/neonatal thymocyte chimeras.** Host animals received splt dose (2 × 550 rad with 24 h interval) before receiving 5 × 10$^6$ donor bone marrow together with 2 × 10$^6$ donor neonatal thymocytes. Mice were kept for another 8 weeks to allow immune system reconstitution.

**Human skin biopsies and primary keratinocyte cell isolation.** All donors signed written informed consent forms in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans (ethical approval number EK647). All samples were obtained from the University Hospital Zurich. Healthy human skin pieces ($\sim$0.5–1 cm$^2$) were incubated overnight at 4°C in CnT07 (CELLnTEC) medium complemented with 1% penicillin, 1% streptomycin (Gibco), 0.5% amphotericin B (Gibco) and 10 μg ml$^{-1}$ dispase (Roche). Afterwards, the epidermis was separated manually and incubated in pre-warmed 0.25% trypsin-EDTA (Gibco) for ~5 min. Keratinocytes were scratched off the epidermis and centrifuged at 1,500 r.p.m. for
Histochemistry. Skin tissue samples were fixed in 4% paraformaldehyde and embedded in paraffin. Mouse skin sections were stained with haematoxylin and eosin according to standard protocols. Deparaffinized human skin sections were embedded in paraffin. Mouse skin sections were stained with haematoxylin and eosin according to standard protocols. Deparaffinized human skin sections were embedded in paraffin.

Statistics. Differences between ≥3 groups were evaluated with one-way or two-way analysis of variance (ANOVA) with Bonferroni’s post test. Differences between two sets of data were evaluated using unpaired two-tailed t-test. Correlation calculation between two parameters has been performed using Pearson’s r (comparable distribution was confirmed via quantile–quantile plots); *P<0.05, **P<0.01, ***P<0.001, NS (not significant). Data were analysed using Prism software (GraphPad Software, Inc.).

Data availability. Sequence data that support the findings of this study have been deposited in the European Nucleotide Archive with the primary accession codes MT514338 and MT514342. The raw data for each of the experiments are provided and all other relevant experimental data can be found in the main text of this article, its Supplementary Information and Supplementary Figures.
1. Lowes, M. A., Suarez-Farinas, M. & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227–255 (2014).

2. Kitagawa, H., Rizzuto, H. L., Lee, J. J., Koguchi, Y. & Blasutti, A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373–1383 (2010).

3. Zaba, L. C. et al. Psoriasis is characterized by accumulation of immunostimulatory and Th17/Th1 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 129, 79–88 (2009).

4. Yawalkar, N., Tscherner, G. G., Hunger, R. E. & Hassan, A. S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J. Dermatol. Sci. 54, 99–105 (2009).

5. Piskin, G., Sylvia-Steenland, R. M., Bos, J. D. & Teunissen, M. B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176, 1908–1915 (2006).

6. Langley, R. G. et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 mononuclear antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 27, 1252–1261 (2013).

7. Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 mononuclear antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).

8. Papp, K. A. et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br. J. Dermatol. 166, 844–854 (2013).

9. Kimball, A. B. et al. Safety and efficacy of ABT-874, a fully human interleukin-12/23 mononuclear antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 144, 200–207 (2008).

10. Di Cesare, A., Di Meglio, P. & Nestle, F. O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129, 1339–1350 (2009).

11. Chan, J. R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577–2587 (2006).

12. Cai, Y. et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 35, 596–610 (2011).

13. van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/Th17 axis. J. Immunol. 182, 5836–5845 (2009).

14. Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathway genes. Nat. Genet. 41, 199–204 (2009).

15. Heilig, J. S. & Tonegawa, S. Diversity of murine gamma genes and expression in fetal and adult T lymphocytes. Nature 322, 836–840 (1986).

16. Pantelyushin, S. et al. Rorgammat cell activation in murine psoriasis. J. Investig. Dermatol. 129, 1350–1354 (2009).

17. Di Meglio, P. et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 40, 989–1001 (2014).

18. Witherden, D. A. & Havran, W. L. Cross-talk between intraepithelial γδ T cells and epithelial cells. J. Leukoc. Biol. 94, 69–76 (2013).

19. Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E. & Krueger, J. G. The IL-23/Th17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34, 174–181 (2013).

20. Bouchaud, G. et al. Epidermal IL-15Rα plays an endogenous antagonist of psoriasis-like inflammation in mouse and man. J. Exp. Med. 210, 2105–2117 (2011).

21. Schwartz, A. et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat. Cell Biol. 4, 26–31 (2002).

22. Schwartz, A. et al. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J. Exp. Med. 201, 173–175 (2005).

23. Schmitt, D. A., Walterscheid, J. F. & Ulrich, S. E. Reversal of ultraviolet radiation-induced immunosuppression by recombinant interleukin-12: suppression of cytotoxic production. Immunology 101, 90–96 (2000).

24. Molenda, M., Mukkamala, L. & Blumenberg, M. Interleukin IL-12 blocks a specific subset of the transcriptional profile responsive to UVB in epidermal keratinocytes. Mol. Immunol. 43, 1933–1940 (2006).

25. Perera, G. K., Di Meglio, P. & Nestle, F. O. Psoriasis. Annu. Rev. Pathol. 7, 345–422 (2012).

26. Gudjonsson, J. E. et al. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J. Invest. Dermatol. 130, 1829–1840 (2010).

27. Chiricozzi, A. et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131, 677–687 (2011).

28. Leonard, C. L. et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014–2022 (2003).

29. Croxford, A. L., Kulig, P. & Becher, B. IL-12 and IL-23 in health and disease. Cytokine Growth Factor Rev. 25, 415–421 (2014).

30. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammatory disease of the brain. Nature 421, 744–748 (2003).

31. Becher, B., Durell, B. G. & Noelle, R. J. Experimental autoimmunencephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 110, 493–497 (2002).

32. Gran, B. et al. IL-12p35–deficient mice are susceptible to experimental autoimmune encephalomyelitic disease for redundancy in the IL-12–23 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169, 7104–7110 (2002).

33. Kopp, T. et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521, 222–226 (2015).

34. Reich, K. et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365, 1586–1596 (2011).

35. Wierzbicka, K. B. et al. Long-term experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J. Am. Acad. Dermatol. 66, 742–751 (2012).
59. Young, L. & Czarnecki, D. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. *Australas. J. Dermatol.* **53**, 57–60 (2012).

60. Ngiow, S. F., Teng, M. W. & Smyth, M. J. A balance of interleukin-12 and -23 in cancer. *Trends Immunol.* **34**, 548–555 (2013).

61. Tugues, S. et al. New insights into IL-12-mediated tumor suppression. *Cell Death Differ.* **22**, 237–246 (2015).

62. Gordon, K. B. et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. *J. Invest. Dermatol.* **132**, 304–314 (2012).

63. Laggner, U. et al. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. *J. Immunol.* **187**, 2783–2793 (2011).

64. Seung, N. R. et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor γδ in plaque and guttate psoriasis. *J. Cutan. Pathol.* **34**, 903–911 (2007).

65. Swindell, W. R., Johnston, A., Voorhees, J. J., Elder, J. T. & Gudjonsson, J. E. Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. *BMC Genomics* **14**, S27 (2013).

66. Banno, T., Gazel, A. & Blumenberg, M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. *J. Biol. Chem.* **279**, 32633–32642 (2004).

67. Vom Berg, J. et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. *J. Exp. Med.* **210**, 2803–2811 (2013).

68. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).

69. Lawrence, M. et al. Software for computing and annotating genomic ranges. *PLoS Comput. Biol.* **9**, e1003118 (2013).

70. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).

Acknowledgements

We thank R.E. Tigelaar for providing us with 17D1 hybridoma. We are grateful for the supply of Il12b−/− mice by E. von Stebut and K. Schwenberg. The excellent technical support and animal husbandry of S. Haider, J. Jaberg, B. Schnautz, J. Grosch and N. Burkhalter is greatly appreciated. The work was partly performed in collaboration with the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University (K.K.) and was supported by grants from the Swiss National Science Foundation (316030 150768, 310030 146130 and CRSII3 136203) (B.B.), European Union FP7 project TargetBrain, NeuroKine and ATECT (B.B.) and the University priority project translational cancer research (B.B.).

Author contributions

P.K. designed and performed most of the experiments, evaluated and interpreted data, wrote the manuscript; S.M. and G.G performed some of the experiments and evaluated the data; S.N.F. performed human keratinocyte isolation; B.S. performed and evaluated skin histology; G.R. evaluated NGS data; F.A. supervised TEWL measurements; S.P. provided technical help with some of the experiments; K.K provided Vδ1−/− mice; F.S., T.K. and G.F.L.H. supervised and/or performed some of the experiments; S.H. designed and performed some of the experiments; S.H. and B.B. evaluated and interpreted data, wrote the manuscript as well as financed and supervised the study.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Kulig, P. et al. IL-12 protects from psoriasiform skin inflammation. *Nat. Commun.* **7**, 13466 doi: 10.1038/ncomms13466 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016